Pharmafile Logo

MK-3102

- PMLiVE

Novo Nordisk to cut 1,000 jobs as diabetes competition builds

Cites intensifying US market in particular for move to reduce costs

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

GSK throws gauntlet down to Merck with shingles vaccine data

Shingrix trial reported ninety per cent efficacy in elderly patients who do not respond well to Zostavax

Sanofi reception

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

AstraZeneca AZ

AZ looks beyond diabetes with Forxiga trials

Will investigate dapagliflozin in kidney disease and heart failure

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

- PMLiVE

Jørgensen named Novo CEO-in-waiting as Sørensen plans retirement

Sørensen’s sooner-than-expected departure sparks executive team reshuffle

FDA approves Lilly-backed Bluetooth insulin device

Clears Companion Medical’s Bluetooth-enabled pen and smartphone app

- PMLiVE

AstraZeneca adds cardiovascular resources to online diabetes programme

Expansion of Fit2Me also includes new Apple and Android mobile apps

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links